BIOLARGO, INC. (BLGO)

0.10 +0.00% (+0.00)

Over 3Y: -37.5%

2026-08-28
0.1 0.2 0.3 0.4
2023 2024 2025 2026

Financials Quarterly

Q3 '21 — Revenue: 712K Q3 '21 — Operating Cash Flow: -908K Q3 '21 — Net Income: -1.4M Q4 '21 — Revenue: 788K Q4 '21 — Operating Cash Flow: -975K Q4 '21 — Net Income: -1.8M Q1 '22 — Revenue: 965K Q1 '22 — Operating Cash Flow: -1.1M Q1 '22 — Net Income: -1.5M Q2 '22 — Revenue: 1.3M Q2 '22 — Operating Cash Flow: -724K Q2 '22 — Net Income: -1.3M Q3 '22 — Revenue: 1.5M Q3 '22 — Operating Cash Flow: -939K Q3 '22 — Net Income: -847K Q4 '22 — Revenue: 2.1M Q4 '22 — Operating Cash Flow: 41K Q4 '22 — Net Income: -1.4M Q1 '23 — Revenue: 3.7M Q1 '23 — Operating Cash Flow: -43K Q1 '23 — Net Income: -494K Q2 '23 — Revenue: 1.4M Q2 '23 — Operating Cash Flow: -1.5M Q2 '23 — Net Income: -1.6M Q3 '23 — Revenue: 2.7M Q3 '23 — Operating Cash Flow: -836K Q3 '23 — Net Income: -1.5M Q4 '23 — Revenue: 4.4M Q4 '23 — Operating Cash Flow: -2K Q4 '23 — Net Income: -1M Q1 '24 — Revenue: 4.8M Q1 '24 — Operating Cash Flow: 481K Q1 '24 — Net Income: -775K Q2 '24 — Revenue: 5M Q2 '24 — Operating Cash Flow: -151K Q2 '24 — Net Income: -780K Q3 '24 — Revenue: 4.4M Q3 '24 — Operating Cash Flow: -1.6M Q3 '24 — Net Income: -1.1M Q4 '24 — Revenue: 3.7M Q4 '24 — Operating Cash Flow: -1.9M Q4 '24 — Net Income: -1.7M Q1 '25 — Revenue: 3.3M Q1 '25 — Operating Cash Flow: -1.8M Q1 '25 — Net Income: -1.9M Q2 '25 — Revenue: 2.8M Q2 '25 — Operating Cash Flow: -2.1M Q2 '25 — Net Income: -1.9M Q3 '25 — Revenue: 1.1M Q3 '25 — Operating Cash Flow: -2.8M Q3 '25 — Net Income: -7.2M Q4 '25 — Revenue: 617K Q4 '25 — Operating Cash Flow: -1.6M Q4 '25 — Net Income: -4.1M Q1 '26 — Revenue: 1.1M Q1 '26 — Operating Cash Flow: -2.9M Q1 '26 — Net Income: -3.4M Q2 '26 — Revenue: 1.2M Q2 '26 — Operating Cash Flow: -3.1M Q2 '26 — Net Income: -4M -5M -2.5M 0 2.5M 5M 7.5M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 80.3%
OE margin -333.1%
Oper. margin -443.9%
Accruals -127.0%
Gross margin 40.0%
EBITDA margin -440.6%
FCF margin -252.8%
OCF margin -252.8%
Profit margin -460.2%
ROA -281.8%
ROCE -951.8%
Capex / sales —
OCF / EBIT —
ROE —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.9
RPO / sales 0.011×
Segment HHI 0.57 HHI
RPO growth —

4 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

1.2
ND/EBITDA —
Current ratio 0.74×
Interest cover -22.5×
Cash / Debt 0.92×
Quick ratio 0.67×
F-score 1.0 pts
Cash runway —
Debt / Eq —
Debt payback —
Equity / Assets —
Net debt / Eq —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

2.3
Sales CAGR 4Y +32.3%
Sales/sh Y/Y -71.8%
Sales Q/Q -55.1%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.